Drug Discovery Featured Articles & Applications

  1. Drug Discovery AI Has A Ground Truth Problem 7/27/2026

    If the goal is more healthy years of life, the bottlenecks are target identification, target validation, and clinical testing. Why is AI not transforming those steps? Because the data are not there.

  2. Fragment-Based Drug Discovery 2.0, Part 2: Practical Workflow, Difficult Target Classes, And Emerging Capabilities 7/27/2026

    Part 2 focuses on the practical workflow, difficult target classes, emerging capabilities, and the criteria for translating these technologies into better discovery decisions.

  3. Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit 7/24/2026

    At BiotechTV’s U.S. Science Summit, biotech leaders discussed China, AI, scientific storytelling, and what it will take to protect U.S. innovation.

  4. Fragment-Based Drug Discovery 2.0, Part 1: Faster, Cleaner Weak-Binding Hit Discovery 7/24/2026

    This article examines the advances in ¹⁹F NMR, ultra-high-field instrumentation, and contrast-engineered screening.

  5. From Path Dependency To Demonstrable Progress: FDA Modernization Act 3.0 7/23/2026

    With House passage of the FDA Modernization Act 3.0, Congress has taken another major step toward modernizing biomedical research and drug development.

  6. How AI-Powered Automation Is Redefining Pharmaceutical R&D 7/23/2026

    The autonomous lab is not a distant aspiration but a present-day competitive differentiator.

  7. Rethinking The Blueprint For Bone Regeneration: The Next Evolution In Orthobiologics 7/22/2026

    Next-generation orthobiologics could transform spinal fusion by enabling targeted bone regeneration, improving safety, and reducing reliance on traditional grafts and hardware.

  8. Pharmacogenomics In Oncology: A Pharmacokinetic Perspective 7/22/2026

    The outcome of a medical treatment is not solely determined by the efficacy of the drug itself. It also depends on the patient’s genetic makeup, biological characteristics of the disease, and individual clinical factors.

  9. From Valency To Vaccine Design: The Changing Competitive Landscape In Pneumococcal Vaccines 7/21/2026

    Pneumococcal vaccination remains one of the strongest success stories in bacterial disease prevention, but the residual burden is now posing new challenges. 

  10. Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3) 7/17/2026

    Rhogam transformed Rh disease prevention, but its plasma-derived, polyclonal biology has resisted decades of synthetic anti-D replacement efforts.